FRA:0A3
Delisted

Acceleron Pharma Stock Forecast

etoro logo Buy 0A3
*Your capital is at risk
159.00€
+0 (+0%)
At Close: Aug 17, 2022

0A3.F Performance

FAQ

What is the symbol for Acceleron Pharma Inc. Stock and on which exchange is it traded?
The symbol for Acceleron Pharma Inc. is 0A3.F and it is traded on the FRA (Frankfurt Stock Exchange).

Should I buy or sell Acceleron Pharma Inc. Stock?
Acceleron Pharma Inc. holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.

How to buy Acceleron Pharma Inc. Stock?
Acceleron Pharma Inc. Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Acceleron Pharma Inc. Stock.

What's the current price of Acceleron Pharma Inc. Stock?
As of the end of day on the Aug 17, 2022, the price of an Acceleron Pharma Inc. (0A3.F) share was 159.00€.

What is the 52-week high and low for Acceleron Pharma Inc. Stock?
The 52-week high for Acceleron Pharma Inc. Stock is 159.00€ and the 52-week low is 101.00€.
Click to get the best stock tips daily for free!
ABOUT ACCELERON PHARMA INC.
Acceleron Pharma
Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine,...
GOLDEN STAR
Ticker Change Signal Date
B
BXDC
$21.71
1.11% Jun 29
SRPT
$17.02
13.28% Jun 29
OSIS
$218.29
1.59% Jun 26
NMRK
$15.02
4.66% Jun 24
JLL
$299.78
9.23% Jun 24

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE